Medicamen Organ. (MEDIORG)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, Medicamen Organ looks like the kind of small, ignored stock Graham would circle: a ₹28 Cr market cap, a P/E of 6.13, and a PEG of 0.29 against 35.10% profit growth. But I have to ask whether this is a real bargain or a value trap. The business is pharmaceuticals, which I understand, but this is a micro-cap with a modest sales growth of only 7.47%. That worries me. Profit growth is outpacing revenue growth by a wide margin, which usually means margin expansion, cost cuts, or a low base — not necessarily durable demand. ROCE at 16.88% is decent, and a Piotroski score of 7/9 suggests the fundamentals are improving. Promoter holding of 59.73% is a good sign; the people running it have skin in the game. Still, too much is missing. No book value, no ROE, no debt-to-equity ratio. I cannot judge financial strength properly without debt numbers, and in a small pharma company, debt and working capital can kill you. There is no dividend, so investors get no cash return while waiting. The latest quarter shows ₹18 Cr sales and ₹2 Cr net profit, so profitability is strong right now, but I need to see whether this is sustainable or a one-off. At 6.13 times earnings, there is some margin of safety if current earnings hold. The 52-week range of ₹19.10 to ₹41.00 tells me this stock can swing wildly. I would not call this a stalwart. It is more like a potential fast grower, but with tiny size, limited data, and modest sales growth, I would keep any position small and demand more evidence before getting excited.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer